FDA gives nod to Novartis cancer biosimilar

05-01-2015

FDA gives nod to Novartis cancer biosimilar

360b / Shutterstock.com

The US Food and Drug Administration (FDA) has recommended that an application by pharmaceutical company Novartis to market a biosimilar version of Amgen’s cancer drug Neupogen (filgrastim) be approved.


Novartis, Sandoz, biosimilars, FDA, Amgen, Neupogen

More on this story

FDA accepts Sandoz biosimilar application
29-07-2014

LSIPR